TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06175624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinically Helathy
Description: Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingivitis
Description: Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontitis
Description: Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
Study: NCT05290389

Intervention type: OTHER
Intervention: SMART AMI APPLICATION
Description: SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician.
Study: NCT05989854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise intervention, 3x/wk
Study: NCT06100393

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Pre-Processing Algorithm (Sub A)
Description: The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear Limited standard-of-care pre-processing algorithms
Description: Automatic Gain Control, SNR-NR, Forward Focus

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear Limited standard-of-care pre-processing algorithms
Description: Automatic Gain Control, SNR-NR, Forward Focus

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Pre-Processing Algorithm (Sub B)
Description: Spatial Automation profile
Study: NCT05854342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicarbonate-calcium water
Description: water with high content of bicarbonate and calcium, low sodium
Study: NCT05654454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6
Study: NCT05574088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical patency with file
Description: After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
Study: NCT05999500

Intervention type: BEHAVIORAL
Intervention: Temple stay experience
Description: Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
Study: NCT04990752

Intervention type: DRUG
Intervention: ulinastatin
Description: In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
Study: NCT05230212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan Breakfast Shake
Description: The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cream Breakfast Shake
Description: The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
Study: NCT05965856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study: NCT04860102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hands on
Description: Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
Study: NCT05263154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed low oxygen
Description: Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High oxygen
Description: FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
Study: NCT05297539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point light display
Description: Visualization of point-light human actions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point light display
Description: Visualization of point-light human actions
Study: NCT06100666

Intervention type: BEHAVIORAL
Intervention: Observational Tests
Description: The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
Study: NCT05762146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylthiouracil
Description: Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Description: Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
Study: NCT04912817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off the Shelf VR
Description: Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom VR
Description: Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
Study: NCT05693506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking workshops
Description: Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking workshops
Description: Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
Study: NCT04845178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, sterile, unpreserved, USP/PhEur
Study: NCT05838092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allo-APZ2-OTS
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06167707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCP-111
Description: Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCP-111
Description: Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide USP
Description: Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide USP
Description: Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
Study: NCT05393557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury
Description: Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
Study: NCT06460896

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacokinetic study
Description: Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
Study: NCT06404151

Intervention type: DEVICE
Intervention: monitoring
Description: rc02, ORI , spO2
Study: NCT06576206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bin therapy and finger gnosia
Description: Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
Study: NCT05798416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exercise under inhalation CO2
Description: Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise under inhalation ambient air
Description: Participants perform shuttle walk test at high altitude while inhaling ambient air
Study: NCT05813158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)
Description: Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)
Description: Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
Study: NCT05172661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated physical-cognitive training
Description: Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consecutive physical-cognitive training
Description: Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
Study: NCT05096936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation
Description: Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
Study: NCT05588102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）
Description: Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）
Description: Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
Study: NCT05629013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-Action Review
Description: After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
Study: NCT04327986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Intravenous (IV) on Days 1 and 15 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Intravenous (IV) on Days 1 and 15 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Intravenous (IV) on Days 1 and 15 of every cycle
Study: NCT06576206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
Study: NCT04327986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Subcutaneous injection on Day 1 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Subcutaneous injection on Day 1 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Subcutaneous injection on Day 1 of every cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
Study: NCT04527861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-incision Laparoscopic Surgery
Description: In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Surgery
Description: In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
Study: NCT05630742

Intervention type: OTHER
Intervention: chronic non-neoplastic pain
Description: comparison of questionnaires scores
Study: NCT05198843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl
Description: Given PO
Study: NCT04384939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic-end Double-J ureteral stent
Description: * Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia.
Study: NCT06172725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and exercise intervention
Description: The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention
Description: The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians.